|
GB201203051D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
KR101503341B1
(ko)
|
2014-03-12 |
2015-03-18 |
국립암센터 |
자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
|
|
AU2016219772A1
(en)
|
2015-02-22 |
2017-09-21 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD137
|
|
AU2016265447B2
(en)
*
|
2015-05-21 |
2022-06-16 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
BR112018076525A2
(pt)
|
2016-06-20 |
2019-04-02 |
F-Star Beta Limited |
membros de ligação a lag-3
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
UA128304C2
(uk)
|
2016-07-14 |
2024-06-05 |
Ґенмаб А/С |
Мультиспецифічне антитіло до cd40 і cd137
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
GB201619648D0
(en)
*
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
EP3544628A4
(en)
*
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1BB BINDING PROTEINS AND THEIR USES
|
|
JP6609724B1
(ja)
|
2017-01-06 |
2019-11-20 |
ユーティレックス カンパニー リミテッド |
抗ヒト４−１ｂｂ抗体およびその使用
|
|
US20180325931A1
(en)
|
2017-01-21 |
2018-11-15 |
Ningbo Zhiming Biotechnology Co., Ltd. |
Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
|
|
JP7132232B2
(ja)
*
|
2017-02-24 |
2022-09-06 |
マクロジェニクス，インコーポレーテッド |
Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
|
JP6743320B1
(ja)
*
|
2017-08-01 |
2020-08-19 |
イーライ リリー アンド カンパニー |
抗ｃｄ１３７抗体
|
|
US11512134B2
(en)
|
2017-08-01 |
2022-11-29 |
Eli Lilly And Company |
Anti-CD137 antibodies
|
|
IL272159B2
(en)
*
|
2017-08-04 |
2026-03-01 |
Genmab As |
PD-L1 and CD137 binding agents and their use
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
SG11202002982YA
(en)
*
|
2017-10-10 |
2020-04-29 |
Numab Therapeutics AG |
Multispecific antibody
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
TWI701259B
(zh)
*
|
2017-11-09 |
2020-08-11 |
大陸商上海懷越生物科技有限公司 |
４﹘１ｂｂ抗體及其製備方法和應用
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019104716A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Adagene Inc. |
Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
|
|
JP7489316B2
(ja)
|
2017-12-19 |
2024-05-23 |
エフ－スター セラピューティクス リミテッド |
Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
AU2019224659A1
(en)
*
|
2018-02-23 |
2020-10-15 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
KR102432046B1
(ko)
|
2018-03-23 |
2022-08-12 |
일라이 릴리 앤드 캄파니 |
항-pd-l1 항체와의 조합을 위한 항-cd137 항체
|
|
US11993655B2
(en)
*
|
2018-04-09 |
2024-05-28 |
Oricell Therapeutics Co., Ltd. |
Anti-PD-L1 antibody and use thereof
|
|
WO2019226617A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
CN119912569A
(zh)
*
|
2018-06-29 |
2025-05-02 |
艾利妥 |
抗SIRP-β1抗体及其使用方法
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811404D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
PL3820569T3
(pl)
|
2018-07-12 |
2025-07-14 |
Invox Pharma Limited |
Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
|
|
AU2019301206B2
(en)
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
US11939381B2
(en)
|
2018-07-19 |
2024-03-26 |
Eli Lilly And Company |
Bispecific antibodies targeting immune checkpoints
|
|
AU2019312200B2
(en)
|
2018-07-23 |
2024-11-14 |
Heidelberg Pharma Research Gmbh |
Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
|
|
CA3105891A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
BR112021004698A2
(pt)
|
2018-09-12 |
2021-06-01 |
Eucure (Beijing) Biopharma Co., Ltd |
anticorpos anti-tnfrsf9 e usos dos mesmos
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CN113518647A
(zh)
|
2018-10-11 |
2021-10-19 |
印希比股份有限公司 |
5t4单域抗体及其治疗性组合物
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
PE20211778A1
(es)
*
|
2018-11-30 |
2021-09-08 |
Abl Bio Inc |
Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos
|
|
JP7558534B2
(ja)
*
|
2019-01-02 |
2024-10-01 |
キューエルエスエフ バイオセラピューティック インコーポレイテッド |
Ｃｄ１３７アゴニスト性抗体とその使用
|
|
EP3911682A4
(en)
*
|
2019-01-14 |
2023-03-15 |
The Regents of the University of California |
COMPOSITIONS AND METHODS TO MODULATE CELLULAR INTERNALIZATION
|
|
JP7554759B2
(ja)
*
|
2019-02-26 |
2024-09-20 |
ソレント・セラピューティクス・インコーポレイテッド |
Ｂｃｍａに結合する抗原結合性タンパク質
|
|
MX2021012961A
(es)
|
2019-04-24 |
2021-11-25 |
Heidelberg Pharma Res Gmbh |
Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
|
|
WO2020247290A1
(en)
*
|
2019-06-04 |
2020-12-10 |
Academia Sinica |
Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
|
|
US11725058B2
(en)
*
|
2019-06-26 |
2023-08-15 |
Ap Biosciences, Inc. |
CD137 antibodies for T-cell activation
|
|
CN114555638B
(zh)
*
|
2019-10-11 |
2023-08-22 |
南京维立志博生物科技有限公司 |
结合4-1bb的抗体及其用途
|
|
US12596122B2
(en)
|
2020-02-05 |
2026-04-07 |
The Board Of Regents Of The University Of Texas System |
LILRB2 antibodies and uses thereof
|
|
WO2021209017A1
(zh)
*
|
2020-04-17 |
2021-10-21 |
苏州丁孚靶点生物技术有限公司 |
一种特异性结合cd137的制剂及其用途
|
|
CA3180665A1
(en)
|
2020-05-19 |
2021-11-25 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
|
CN113842456B
(zh)
*
|
2020-06-28 |
2022-07-26 |
上海齐鲁制药研究中心有限公司 |
一种抗人4-1bb的单克隆抗体制剂及其用途
|
|
CN116194124A
(zh)
*
|
2020-07-31 |
2023-05-30 |
中外制药株式会社 |
包含表达嵌合受体的细胞的药物组合物
|
|
WO2023098785A1
(zh)
*
|
2021-12-01 |
2023-06-08 |
上海君实生物医药科技股份有限公司 |
抗4-1bb抗体及其用途
|
|
CN115975032B
(zh)
*
|
2022-12-19 |
2024-06-07 |
华润生物医药有限公司 |
一种cldn18.2抗体及其应用
|
|
AU2024330458A1
(en)
*
|
2023-09-01 |
2026-02-12 |
Amgen Inc. |
Molecules for treatment of cancer
|
|
WO2025189194A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against vegf and methods of use thereof
|